✦ LIBER ✦

A useful high-dose intermittent schedule of adriamycin and DTIC in the treatment of advanced sarcomas

✍ Scribed by John H. Saiki; Laurence H. Baker; Saul E. Rivkin; Salah Shahbender; William S. Fletcher; John W. Athens; Stanley P. Balcerzak; John D. Bonnet

Publisher: John Wiley and Sons
Year: 1986
Tongue: English
Weight: 223 KB
Volume: 58
Category: Article
ISSN: 0008-543X
DOI: 10.1002/1097-0142(19861115)58:10<2196::aid-cncr2820581005>3.0.co;2-j

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Is Low-dose Aspirin a Useful Adjuvant Th

Is Low-dose Aspirin a Useful Adjuvant Therapy in the Treatment of NIDDM?

✍ Mubarak, Ahmed A.S. 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 26 KB 👁 1 views

between 5.5 and 10 mmol l Ϫ1 . In May There is increasing evidence supporting the use of aspirin in patients with non-1996, fasting blood glucose was

A phase II study of intravenously-admini

A phase II study of intravenously-administered methyl CCNU in the treatment of advanced sarcomas

✍ Paul Chang; Marshall A. Levine; Peter H. Wiernik; Michael D. Walker 📂 Article 📅 1976 🏛 John Wiley and Sons 🌐 English ⚖ 392 KB 👁 2 views

Thirty-two patients with advanced, inoperable nonhematologic soft-tissue and osseous sarcomas were treated with Methyl CCNU administered via controlled intravenous infusion in doses of 130-170 mg/m2 every 6 weeks in a Phase I1 trial. All 28 evaluable patients were no longer responsive to adriamycin.

A phase II evaluation of methyl CCNU and

A phase II evaluation of methyl CCNU and actinomycin D in the treatment of advanced sarcomas in adults

✍ Boh-Seng Yap; Robert S. Benjamin; Michael A. Burgess; William K. Murphy; Joseph 📂 Article 📅 1981 🏛 John Wiley and Sons 🌐 English ⚖ 280 KB 👁 2 views

Twenty-nine patients with metastatic sarcoma were treated with a combination of methyl CCNU and actinomycin D. Patients with adequate bone marrow reserve received methyl CCNU 100 mg/m2 orally on day 1 and actinomycin D 0.3 mg/m2/day intravenously for five days. Both drugs were repeated every four we

The current place of high-dose immunoglo

The current place of high-dose immunoglobulins in the treatment of neuromuscular disorders

✍ Frans G. A. van der Meché; Pieter A. van Doorn 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 114 KB 👁 1 views

High-dose immunoglobulins for intravenous administration (IVIg) have originally been developed for substitution therapy in hypogammaglobulinemia. Over the last decade they are increasingly used in the treatment of immunemediated diseases. In this review the results in immune-mediated neuromuscular d

Synergistic action of high-dose hydroxyu

Synergistic action of high-dose hydroxyurea when used with cyglophosphamide and certain new organoplatinum complexes in treatment of advanced L1210 leukemia

✍ Glen R. Gale; Loretta M. Atkins; Sandra J. Meischen; Paul Schwartz 📂 Article 📅 1978 🏛 John Wiley and Sons 🌐 English ⚖ 394 KB

A phase I/II study of sequential, dose-e

A phase I/II study of sequential, dose-escalated, high dose ifosfamide plus doxorubicin with peripheral blood stem cell support for the treatment of patients with advanced soft tissue sarcomas

✍ Carsten Bokemeyer; Anke Franzke; Jörg T. Hartmann; Christoph Schöber; Lubomir Ar 📂 Article 📅 1997 🏛 John Wiley and Sons 🌐 English ⚖ 85 KB 👁 2 views

ide combined with full dose doxorubicin chemotherapy supported with peripheral blood stem cells (PBSC) and granulocyte-colony stimulating factor (G-CSF) in